arrow
R

R. Vidal Tocino

hospital universitario de salamanca
H指数:8
被引数:219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial

索托拉西布联合帕尼单抗和5-氟尿嘧啶在不可切除的KRAS G12C突变结直肠癌患者一线治疗中的应用(不适用双药/三药化疗):ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO试验

2026-05-010
OAAI
Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort

胃食管腺癌中Claudin 18.2的表达: 生物标志物重叠及其与欧洲队列临床结果的关联

2026-01-270
OAAI
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study

一种基于外泌体的液体活检技术用于早期结直肠癌的检测:ENCODER多中心研究

2025-12-090
OAAI
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis

围术期FLOT疗法是否能提高可切除食管腺癌的治愈率?——混合治愈模型分析

2025-11-260
OAAI
Real-World Molecular Testing in European Early-Onset Colorectal Cancer

欧洲早发性结直肠癌的真实世界分子检测

2025-09-270
OAAI
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry

西班牙接受全身治疗肝细胞癌患者的实际管理及预后:来自RETUD消化道登记研究的患者队列

2025-08-090
OA
Immigrant Health and Early-Onset Colorectal Cancer Disparities: Results From the Spanish Early-Onset Colorectal Cancer Consortium
2024-11-010
OA
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
2023-11-151
PRE
Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
2023-10-010
PRE
Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
2023-10-010
PRE
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Agamenon-seom模型预测接受基于曲妥珠单抗的一线治疗的晚期HER2-positive食管胃腺癌患者的生存

2023-03-041
OAAI